TH63235B - Antibody - Google Patents

Abstract

DC60 (02/08/48) Polypeptides or protein complexes with light chain derivative compounds. Or the weight of the antibodies that are attached to P-selectin glycoprotein ligand-1 Also disclosed are nucleic acids encoded polypeptides, vectors and host cells containing nucleic acids, and a method for inducing activated T-cell death. And modulation of the immune response mediated by intra-animal T cells, polypeptides or protein complexes with light-chain reconstituted compounds. Or the weight of the antibodies that are attached to P-selectin glycoprotein ligand-1 Also disclosed are nucleic acids encoded polypeptides, vectors and host cells containing nucleic acids, and a method for inducing activated T-cell death. And modulation of the immune response mediated by T cells within laboratory animals.

Claims (1)

1.1.-18 respectively 1., 20, 21, 22, 23, 24, 25 or 26 3. The separated nucleic acid composed of the polypeptide encoded sequence according to the claim. 1 4. Vector composed of nucleic acids according to claim 3 5. Host cell composed of nucleic acid according to claim 3 6. Host cell according to claim 5 where the cell is Bacterial cells, yeast cells, plant cells, insect cells or mammalian cells 7. Polypeptide formation method composed by host cell culture according to claim 5 in food under conditions that The expression of polypeptides encoded by nucleic acids and polypeptide purification from cultured cells is allowed. Or cell food 1.-18 respectively 1. 1 0. Protein complexes according to claim 8, wherein the protein complexes strongly bind Human specific P-selectin glycoprotein ligand 1 1 1. Protein complexes according to claim 10, while binding to P-selectin glycoprotein ligand 1 on T-cells that are stimulated Induce the death of T-cells stimulated 1 2. Protein complexes according to claim 8, where the second polypeptide consists of regions. Stabilizers of heavy chains of immunoglobulin. (immunoglobulin heavy chain constant region) 1 3. Protein complexes as per claim 12, where protein complexes are antibodies 1. 4. Protein complexes according to claim 13, where antibodies are monoclo. Nal, chimeric or humenisade antibodies 1 5. Protein complexes that bind exclusively to the human P-zelectin glycoprotein ligand 1 without inhibition of inhibition. Binds between P-selectin, glycoprotein, ligand1 and P-selectin, where protein complexes while binding to P-selectin, glycoprotein, ligand 1 on activated T-cells. Induce the death of T-cells activated 1 1. 6 respectively 1 1. respectively 1. 8. Protein complexes according to claim 15, where the second polypeptide contains Immunoglobulin heavy chain fixed area 1 9. Protein complex according to claim 18, where protein complex is an antibody 2 0. Protein complex according to claim 19, whereby The antibodies are monoclonal, chimeric or humenisade antibodies 2. 1. Protein complexes, which are specifically bound to the amino acid residewase 115-126 of He. P-selectin, glycoprotein, ligand 1 2 2. protein complexes according to claim 21, where protein complexes While gripping with P-zelectin, glycoprotein, ligand 1 on T-stimulated T cells, including death of T-cells stimulated, 2 1. 6, respectively, 2 1., respectively, 2. 5. Protein complexes according to the cell. Rights 21, where the second polypeptide contains Immunoglobulin heavy chain fixed area 2 6. Protein complex according to claim 25, where protein complex is an antibody 2 7. Protein complex according to claim 26, where The antibodies are monoclonal, chimeric or humanoid antibody 2 2 8. Methods for inducing death of T-cells that are stimulated Which consists of exposure to substances Any complex of claims 8, 15 or 21 with T-cells stimulated. Where the binding of substances Protein complexes with T cells activated Induced T cell death induced 2 9. Modulation methods of immune response mediated by T cells in laboratory animals, including: Identification of whether laboratory animals are or are at risk of obtaining a given condition. Characteristic by response Immunologic activity mediated by excess T cells; And the use of protein complexes in accordance with any claim 8, 15 or 21. In quantities that were effective to laboratory animals 3 0. Method according to claim 29, where the condition is inflammatory disease, autoimmune disease, allergies or 3 T cell carcinoma. 1. Method according to claim 29, where the animal receives Or was considered to have received allogeneic or xenogeneic tissue implants.